ArticleTransplantation direct2026
Effects of End-ischemic Hypothermic Oxygenated Perfusion on 1-y Graft Function in Kidney Transplantation: A Real-world, Single-center Analysis From the United States.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypothermic oxygenated perfusion (HOPE) supplies oxygen to kidney allografts for resuscitation before transplantation and may improve graft recovery. This study represents the first U.S.-based comparative analysis evaluating the impact of HOPE on kidney transplant (KT) outcomes. Methods: A retrospective, single-center study of adult, deceased-donor, kidney-only transplants performed between December 1, 2023, and March 31, 2025. Transplants were grouped according to preservation method: HOPE, static cold storage (SCS), or hypothermic machine perfusion (HMP) without oxygen alone. The primary outcome was 12-mo estimated glomerular filtration rate (eGFR). Subgroup analyses were performed, including donation after circulatory death (DCD) and long cold ischemic time (>18 h) KT. A matched cohort analysis was performed for DCD-KT. Kruskal-Wallis rank-sum and pairwise comparisons were used. Results: Among 279 KT, 137 (49.1%) used SCS, 56 (20.1%) HOPE, and 86 (30.8%) HMP. There were few differences in baseline characteristics between groups, including donor age, kidney donor profile index, donor serum creatinine, and recipient age. Preservation time was significantly longer with HOPE (median 27.9 versus SCS 18.3 versus HMP 20.2 h; Conclusions: HOPE preservation is associated with improved long-term graft function compared with HMP while maintaining outcomes compared with SCS despite longer preservation times, with notable benefits in DCD-KT.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.